Navigation Links
Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for XYOTAX(TM)
Date:3/4/2008

d less time in the doctor's office or hospital are important benefits for these patients," said James A. Bianco, M.D., President and CEO of CTI. "We appreciate the efforts of all the people who made this submission possible, especially the investigators and patients who participated in the clinical trials."

CTI also has an ongoing phase III clinical trial, in conjunction with the Gynecologic Oncology Group (GOG), studying XYOTAX as monthly maintenance treatment in ovarian cancer.

About Lung Cancer

Lung cancer is the most common malignancy worldwide. Non-small cell lung cancer (NSCLC) accounts for 80 percent of all lung cancer cases. Within the population of patients with NSCLC requiring chemotherapy, PS2 patients, which account for approximately 25 percent of this group, are a population with special requirements since they have poor survival with cytotoxic chemotherapy and targeted agents. PS2 patients represent a subgroup of patients who are ambulatory and capable of self-care, but are unable to carry out any work activities, although they are up and about more than 50 percent of waking hours. There are presently no drugs approved to treat PS2 patients with advanced NSCLC.

Lung cancer remains the biggest cancer killer in Europe. The incidence of lung cancer in Europe is more than 13 percent of all cancers, and in 2000 resulted in nearly 350,000 deaths.

About XYOTAX(TM)

XYOTAX(TM) (paclitaxel poliglumex, CT-2103) is an investigational, biologically enhanced, chemotherapeutic that links paclitaxel, the active ingredient in Taxol(R), to a biodegradable polyglutamate polymer, which results in a new chemical entity. When bound to the polymer, the chemotherapy is rendered inactive, potentially sparing normal tissue's exposure to high levels of unbound, active chemotherapy and its associated toxicities. Blood vessels in tumor tissue, unlike blood vessels in normal tissue, are porous to molecules like polyglutamate. Based on precl
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
2. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
3. Cell Therapeutics, Inc. (CTI) Supports Panel Discussion on Women and Lung Cancer on Capitol Hill
4. Velcura Therapeutics, Inc. Reports Positive Pre-IND Meeting With FDA and Plans Early Clinical Trials for New Drug to Treat Multiple Myeloma Bone Disease
5. NIST Awards $2 Million to Velcura Therapeutics, Inc. for Innovative Technology R&D - Dual-Action Therapies for Bone Disease
6. Ocera Therapeutics, Inc. Completes Enrollment in FHAST1, a Pivotal Phase 3 Clinical Trial in Fistulizing Crohns Disease
7. William R. Ringo Joins Hyperion Therapeutics, Inc. Board of Directors as Chairman
8. BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health
9. Peregrine Pharmaceuticals Submits Clinical Protocol to Initiate Bavituximab Phase II Trial in Patients With Metastatic Breast Cancer
10. Vanda Pharmaceuticals Submits Iloperidone New Drug Application
11. Peregrine Pharmaceuticals Submits Clinical Protocol for New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... NOT FOR RELEASE, PUBLICATION OR ... INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD ... SUCH JURISDICTION. AbbVie (NYSE: ABBV ) ... 25, 2014, before the market opens. AbbVie will ... 8 a.m. Central time (9 a.m. Eastern). It will be ...
(Date:7/23/2014)... 23, 2014 Research and Markets ... "Global Electrophysiology Ablation Catheters Market 2014-2018" report ... http://photos.prnewswire.com/prnh/20130307/600769 Catheter ablation is a ... faulty electrical pathways from sections of the heart ... cardiac arrhythmias). Cardiac arrhythmias can be of several ...
(Date:7/23/2014)...  Nonin Medical, Inc., the inventor of finger pulse ... today that Mark VanderWerf , Nonin,s Vice President ... the American Telemedicine Association,s (ATA) Industry Council and will ... ATA is the leading international resource and advocate promoting ... and its diverse membership work to transform healthcare to ...
Breaking Medicine Technology:AbbVie to Host Second-Quarter Earnings Conference Call 2AbbVie to Host Second-Quarter Earnings Conference Call 3AbbVie to Host Second-Quarter Earnings Conference Call 4AbbVie to Host Second-Quarter Earnings Conference Call 5AbbVie to Host Second-Quarter Earnings Conference Call 6Global Electrophysiology Ablation Catheters Market 2014-2018: Key Vendors are Boston Scientific, Johnson & Johnson, Medtronic and St. Jude Medical 2Global Electrophysiology Ablation Catheters Market 2014-2018: Key Vendors are Boston Scientific, Johnson & Johnson, Medtronic and St. Jude Medical 3Nonin Medical Announces that Mark VanderWerf has been Elected Chairman of the American Telemedicine Association's Industry Council 2
... Rochester Medical Implants ( http://www.rmi.us.com ), a contract manufacturer ... it has relocated corporate offices and manufacturing operations to ... the location change, the company will change its name ... The new facility is a modern 33,000-square ...
... Calif., Oct. 17, 2011 ChemoCentryx, Inc., today ... trial for CCX168, an orally-administered small molecule for ... (AAV), a disease which can lead to renal ... receptor (C5aR), a potent pro-inflammatory mediator that is ...
Cached Medicine Technology:Rochester Medical Implants Relocates to New Facility in Noblesville, IN 2ChemoCentryx Initiates Phase II Clinical Trial for CCX168, a Novel Small Molecule C5aR Antagonist for the Treatment of Vasculitis 2ChemoCentryx Initiates Phase II Clinical Trial for CCX168, a Novel Small Molecule C5aR Antagonist for the Treatment of Vasculitis 3ChemoCentryx Initiates Phase II Clinical Trial for CCX168, a Novel Small Molecule C5aR Antagonist for the Treatment of Vasculitis 4
(Date:7/23/2014)... 2014 (HealthDay News) --,Jealousy may not be the sole ... get downright possessive when it comes to the love ... toward what was actually a stuffed dog, the real ... the stuffed dog aside, report researchers from the University ... only surfaced when owners were attending to the stuffed ...
(Date:7/23/2014)... effort to catalog the molecular causes of stomach ... have identified four subtypes of tumors based on ... the new classification promises to advance clinical research ... killer worldwide. , In a report in ... Research Network said they analyzed 295 samples of ...
(Date:7/23/2014)... 2014 Texas Physical Therapy Specialists (TexPTS) ... their Westlake, Westgate, Liberty Hill, Parmer, Balcones, and Georgetown ... of Orthopaedic Certified Specialist (OCS) or ... PT, DPT, OCS, Tony Lauretta, PT, DPT, OCS, Jason ... Joseph Leech, PT, DPT, OCS, and Mary Grimberg, PT, ...
(Date:7/23/2014)... A therapy combining salmon fibrin injections into the spinal ... brain restored voluntary motor function impaired by spinal cord ... found. , In a study on rodents, Gail Lewandowski ... the developmental clock in a molecular pathway critical to ... a scaffold so that neuronal axons at the injury ...
(Date:7/23/2014)... North American market was valued at $985.4 million in 2012. ... 10.79%, to reach $1,801.1 million by 2018. Organobromines is the ... Bromine Market report defines and segments the bromine market in ... the TOC of the North American Bromine Market report, to ... provides a glimpse of the segmentation in the North America ...
Breaking Medicine News(10 mins):Health News:Dogs Can Get Jealous, Too 2Health News:New view of stomach cancer could hasten better therapies 2Health News:New view of stomach cancer could hasten better therapies 3Health News:Texas Physical Therapy Specialists Congratulates New Board Certified Specialists 2Health News:Texas Physical Therapy Specialists Congratulates New Board Certified Specialists 3Health News:Gene inhibitor, salmon fibrin restore function lost in spinal cord injury 2Health News:North America Bromine Market is Expected to Reach $1801.1 million in 2018 - New Report by MicroMarket Monitor 2Health News:North America Bromine Market is Expected to Reach $1801.1 million in 2018 - New Report by MicroMarket Monitor 3Health News:North America Bromine Market is Expected to Reach $1801.1 million in 2018 - New Report by MicroMarket Monitor 4
... ... drug efficacy and reducing side effects , ... Santa Barbara, Calif. (Vocus) April 8, 2010 -- Researchers have ... penetrate deeply into tumor tissue. The peptide has been shown to substantially increase treatment ...
... effective as blood thinner, study finds , THURSDAY, April 8 ... works as well as medication -- and is safer -- ... device is as useful as blood thinners for the reduction ... safety," said study co-author Dr. Douglas E. Padgett, chief of ...
... have resulted in extended and repeated combat-related deployments of U.S. ... problems, both physical and psychological, many bring back with them, ... home can have issues as well. The ... quickly adjust to altered family roles and the stress of ...
... can take in the waiting room may lead to ... News) -- A researcher has developed a brief ... suffering from the early memory and reasoning problems that ... the journal Alzheimer Disease and Associated Disorders , ...
... under Singapore,s Agency for Science, Technology and Research (A*STAR), ... (SIgN), are collaborating with Italy,s Siena Biotech S.p.A. to ... potentially help millions of cancer and bone loss patients ... collaboration A*STAR has with research centres and universities in ...
... others interested in the chemical sciences are invited to ... Society (ACS) Webinars, focusing on Professional Growth and Development. ... p.m. Eastern Time, the free webinar will feature Martin ... years of experience working on immigration visas for scientists, ...
Cached Medicine News:Health News:Research Reveals Cancer Drug Effectiveness Substantially Advanced 2Health News:Research Reveals Cancer Drug Effectiveness Substantially Advanced 3Health News:Research Reveals Cancer Drug Effectiveness Substantially Advanced 4Health News:Research Reveals Cancer Drug Effectiveness Substantially Advanced 5Health News: Compression Device May Outperform Meds After Hip Surgery 2Health News:Children of combat-deployed parents show increased worries, even after parent returns 2Health News:Simple Memory Test May Detect Early Alzheimer's 2Health News:Exploring the 'Davids and Goliaths' of therapeutic molecules 2Health News:Exploring the 'Davids and Goliaths' of therapeutic molecules 3Health News:ACS Webinar focuses on immigration law for scientific professionals 2
300 L, Bulk Recommended for 250 and 300 L pipettes. Can also be used with 20, 25, 50, 100 and 200 L pipette...
Its MicroPoint design and reference marks at 10, 50 and 100 L ensure accurate performance with a variety of multi-channel and single-channel pipettors....
... its wide orifice tip, the Finntip Wide ... suspensions and macromolecules like genomic DNA. This ... cell fragmentation. It is excellent for use ... model, the inside diameter of the orifice ...
MBP's equivalent to the "Universal Yellow" tip, this 200 ul tip utilizes a MicroPoint design for accurate sample handling. 10 L Ref. mark....
Medicine Products: